About Auxagen

             Auxagen, Inc. was founded in 2004 to develop TGF-β receptor antagonists to treat wounds and tissue fibrosis which currently lack effective therapy. Many lines of evidence indicate that TGF-β is an ideal target for developing novel therapeutic agents to treat wounds and tissue fibrosis. We have developed novel TGF-β receptor antagonist products which exhibit potent TGF-β antagonist activity and growth promoting effects on epithelial and endothelial cells. These products are effective in enhancing wound healing and reducing scarring by topical administration and in ameliorating and reversing lung fibrosis by intranasal administration in relevant animal models. These products are currently in preclinical trials. An ongoing SBIR phase II study on wound treatment is expected to result in an IND filing in 2013. A SBIR phase I study on lung fibrosis treatment has been completed.